Literature DB >> 10950030

Health-related quality of life and severity of symptoms in patients with Barrett's esophagus and gastroesophageal reflux disease patients without Barrett's esophagus.

M A Eloubeidi1, D Provenzale.   

Abstract

OBJECTIVES: The aims of this study were: 1) to compare the health-related quality of life (HRQL) of patients with Barrett's esophagus (BE) to that of patients with GERD who did not have BE; 2) to compare HRQL of gastroesophageal reflux disease (GERD) patients to that of normative data for the US general population; and 3) to examine the impact of GERD symptom frequency and severity on HRQL.
METHODS: The SF-36 and a validated GERD questionnaire were administered to 107 patients with biopsy-proven BE and to 104 patients with GERD but no BE by endoscopy. Frequent symptoms were defined as symptoms that occurred at least once weekly. Severity of symptoms was rated on a scale from 1 to 4 (mild to very severe).
RESULTS: In all, 85% of the GERD patients and 82% of BE patients completed the questionnaires. There was no difference in the scores of the eight subscales of the SF-36 between BE patients and those with GERD but without BE (p > 0.05). However, both groups scored below average on all subscales of the SF-36 compared to published US norms for an age- and gender-matched group. Using multivariable linear regression, the social functioning subscale of the SF-36 correlated with the presence of heartburn or acid regurgitation, severity of acid regurgitation, frequency of heartburn, frequency of acid regurgitation, and number of comorbidities. Similarly, the physical functioning subscale correlated with age, frequency of heartburn, and number of comorbidities. The bodily pain subscale correlated with the frequency of heartburn and number of comorbidities. The bodily pain subscale correlated with the frequency of heartburn and the severity of dysphagia, whereas the role emotional subscale correlated with the frequency of heartburn and the presence of dysphagia.
CONCLUSIONS: Although there were no differences in HRQL between BE and GERD patients, both groups scored below average on the subscales of the SF-36 compared to normal controls. GERD symptom frequency and severity were associated with bodily pain and with impaired social, emotional, and physical functioning, suggesting a profound impact on daily living.

Entities:  

Mesh:

Year:  2000        PMID: 10950030     DOI: 10.1111/j.1572-0241.2000.02235.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  22 in total

Review 1.  The impact of gastroesophageal reflux disease on quality of life.

Authors:  T Kamolz; R Pointner; V Velanovich
Journal:  Surg Endosc       Date:  2003-06-13       Impact factor: 4.584

2.  Quality of life in GERD and Barrett's esophagus is related to gender and manifestation of disease.

Authors:  Quinn K Lippmann; Seth D Crockett; Evan S Dellon; Nicholas J Shaheen
Journal:  Am J Gastroenterol       Date:  2009-09-15       Impact factor: 10.864

Review 3.  Patient reported outcomes in gastroesophageal reflux disease: an overview of available measures.

Authors:  Nicholas J Talley; Ingela Wiklund
Journal:  Qual Life Res       Date:  2005-02       Impact factor: 4.147

4.  Different Quality of Life Between GERD and Barrett's Esophagus (Am J Gastroenterol 2009;104:2695-2703).

Authors:  Su Youn Nam
Journal:  J Neurogastroenterol Motil       Date:  2010-04-27       Impact factor: 4.924

Review 5.  Health-related quality of life in patients with Barrett's esophagus: a systematic review.

Authors:  Seth D Crockett; Quinn K Lippmann; Evan S Dellon; Nicholas J Shaheen
Journal:  Clin Gastroenterol Hepatol       Date:  2009-03-10       Impact factor: 11.382

6.  Postmenopausal hormone therapy as a risk factor for gastroesophageal reflux symptoms among female twins.

Authors:  Helena Nordenstedt; Zongli Zheng; Alan J Cameron; Weimin Ye; Nancy L Pedersen; Jesper Lagergren
Journal:  Gastroenterology       Date:  2008-01-11       Impact factor: 22.682

7.  Symptoms, acid exposure and motility in patients with Barrett's esophagus.

Authors:  Michael G Brandt; Gail E Darling; Linda Miller
Journal:  Can J Surg       Date:  2004-02       Impact factor: 2.089

8.  Risk factors for Barrett's esophagus among patients with gastroesophageal reflux disease: a community clinic-based case-control study.

Authors:  Zoe R Edelstein; Mary P Bronner; Sheldon N Rosen; Thomas L Vaughan
Journal:  Am J Gastroenterol       Date:  2009-03-24       Impact factor: 10.864

9.  On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction.

Authors:  Julio Ponce; Lidia Argüello; Guillermo Bastida; Marta Ponce; Vicente Ortiz; Vicente Garrigues
Journal:  Dig Dis Sci       Date:  2004-06       Impact factor: 3.199

10.  Rabeprazole 20 mg for erosive esophagitis-associated symptoms in a large, community-based study: additional results.

Authors:  Alan Cutler; Malcolm Robinson; Anita Murthy; Byron Delemos
Journal:  Dig Dis Sci       Date:  2009-06-26       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.